Trial Profile
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Selitrectinib (Primary)
- Indications Cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Bayer; Loxo Oncology
- 08 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2019 According to a American Association for Cancer Research Media Release, data from the trial was presented in the AACR Annual Meeting 2019, March 29 to April 3.